Avalon GloboCare (Nasdaq:ALBT) - Cotización, noticias y análisis

Resumen de acción ALBT

Avalon GloboCare Corp., junto con sus filiales, posee y explota propiedades inmobiliarias comerciales en Estados Unidos. Saber más

Análisis fundamental de ALBT
Puntuación del snowflake
Valoración	0/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	0/6
Dividendos	0/6

Análisis de riesgos

No tiene una capitalización de mercado significativa ($3M)

Tiene unos ingresos inferiores a 1 millón de dólares ($-8M)

Tiene menos de 1 año de cash runway

Alta volatilidad del precio de la acción en los últimos 3 meses

+ 1 riesgos adicionales

Competidores de Avalon GloboCare Corp.

Ucommune International

NasdaqCM:UK

US$1.7m

Tuxis

OTCPK:TUXS

US$2.6m

Broad Street Realty

OTCPK:BRST

US$3.7m

New Concept Energy

NYSEAM:GBR

US$6.2m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Avalon GloboCare
Precios históricos de las acciones
Precio actual de la acción	US$3.02
Máximo en las últimas 52 semanas	US$21.60
Mínimo de 52 semanas	US$2.11
Beta	0.31
1Cambio en 1 mes	-7.22%
Variación en 3 meses	-39.58%
Cambio de 1 año	-63.72%
3Variación en 3 años	-97.99%
Variación en 5 años	-98.66%
Variación desde la OPV	-97.12%

Noticias y actualizaciones recientes

Recent updates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

Jan 30

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

Jan 04

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Nov 30

Rentabilidad de los accionistas

	ALBT	US Real Estate	Mercado US
7D	-12.2%	-4.6%	-0.5%
1Y	-63.7%	26.6%	32.3%

Rentabilidad vs. Industria: Los resultados de ALBT fueron inferiores a los de la industria US Real Estate, que obtuvo un rendimiento del 26.6% el año pasado.

Rentabilidad vs. Mercado: ALBT obtuvo unos resultados inferiores a los del mercado US, que fueron del 32.3% el año pasado.

Volatilidad de los precios

Is ALBT's price volatile compared to industry and market?
ALBT volatility
ALBT Average Weekly Movement	27.2%
Real Estate Industry Average Movement	8.1%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de ALBT ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ALBT ha disminuido de 50% a 27% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2016	5	David Jin	www.avalon-globocare.com

Avalon GloboCare Corp., junto con sus filiales, posee y explota propiedades inmobiliarias comerciales en Estados Unidos. La empresa se centra en desarrollar servicios de diagnóstico y laboratorio clínico mediante la adquisición de propiedad o derechos de licencia en activos de diagnóstico de precisión, pruebas genéticas y empresas de laboratorio clínico a través de empresas conjuntas y estructuras de propiedad compartida o derechos de distribución. La empresa se fundó en 2016 y tiene su sede en Freehold, Nueva Jersey.

Resumen de fundamentos de Avalon GloboCare Corp.

¿Cómo se comparan los beneficios e ingresos de Avalon GloboCare con su capitalización de mercado?
Estadísticas fundamentales de ALBT
Capitalización bursátil	US$3.32m
Beneficios(TTM)	-US$14.73m
Ingresos (TTM)	n/a

-0.4x

Ratio precio-ventas (PS)

-0.2x

Ratio precio-beneficio (PE)

¿Está ALBT sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ALBT
Ingresos	-US$8.32m
Coste de los ingresos	US$1.03m
Beneficio bruto	-US$9.35m
Otros gastos	US$5.38m
Beneficios	-US$14.73m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-13.83
Margen bruto	112.38%
Margen de beneficio neto	177.07%
Ratio deuda/patrimonio	160.5%

¿Cómo se ha desempeñado ALBT a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ALBT

Análisis de riesgos

Competidores de Avalon GloboCare Corp.

NasdaqCM:UK

US$1.7m

OTCPK:TUXS

US$2.6m

OTCPK:BRST

US$3.7m

NYSEAM:GBR

US$6.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings released: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific and Clinical Advisory Board

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Recent updates

Third quarter 2024 earnings released: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific and Clinical Advisory Board

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022)

Avalon GloboCare Corp. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021)

Avalon GloboCare Corp. announced that it expects to receive $11 million in funding

Avalon GloboCare Regains Compliance with the Minimum Bid Requirement

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021)

Insufficient new directors

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million.

We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt

Avalon GloboCare Receives Second Letter from the Staff of Nasdaq

Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021)

Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

Avalon GloboCare Corp. announced that it has received $3.718943 million in funding

Insufficient new directors

Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?

Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board

First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020)

Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020)

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Director William Stilley has joined 3rd company board

Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020)

Avalon GloboCare Corp.(NasdaqCM:AVCO) dropped from Russell Microcap Value Index

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million.

Avalon Globocare to acquire SenlangBio in all-stock deal

First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020)

Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?

Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019)

A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns

New 90-day high: US$1.59

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

New 90-day high: US$1.33

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Third quarter 2020 earnings released: US$0.04 loss per share

New 90-day low: US$1.12

Avalon GloboCare Provides Clinical Updates on its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

New 90-day low: US$1.15

New 90-day low - US$1.54